Although carbapenems are effective for treating serious multidrug-resistant Pseudomonas
aeruginosa infections, carbapenem-resistant P. aeruginosa (CRPA) is now being reported …

Evaluation of: Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+ NXL104
against Pseudomonas aeruginosa and other non-fermenters. J. Antimicrob. Chemother. 65 …

The interactions of ceftobiprole with purified β-lactamases from molecular classes A, B, C,
and D were determined and compared with those of benzylpenicillin, cephaloridine …

Background This study aimed to investigate the in vitro activity of cefoperazone–sulbactam
against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, and …

The resistance rates of ampicillin/sulbactam 2: 1 against imipenem-susceptible and-resistant
Acinetobacter baumannii were 23.5 and 30%, respectively. Ceftazidime/sulbactam …

Objectives To evaluate the antimicrobial activities of cefoperazone-sulbactam and
comparator agents tested against a large collection of clinical isolates of Gram-negative …

Background Early β-lactamase inhibitors were combined with established penicillins, but
different combinations may be more appropriate to counter current β-lactamase threats, with …

Cefoperazone, a cephalosporin which inhibits most Enterobacteriaceae, Pseudomonas
aeruginosa and Staphylococcus aureus, is hydrolyzed by some β-lactamases. Combination …

The rise in resistant Gram-negative bacteria is a major concern and has led to difficulty in
treating multidrug-resistant (MDR) infections. Two recently approved combination antibiotics …

Ceftobiprole medocaril is the first member of a new series of advanced cephalosporins with
activity against methicillin‐resistant Staphylococcus aureus (MRSA). The drug received an …